Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 3
Chunk 1
---
 affect our commercialization prospects;  

  If we are unable to obtain and maintain effective patent rights for our products, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of ou...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If we are unable to maintain effective proprietary rights for our products, we may not be able to compete effectively in our markets;  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We may face future claims that our personnel improperly used or disclosed third-party confidential information or trade secrets from prior employers;  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our financial statements for the year ended December 31, 2024, contained a going concern disclosure in Note 1 regarding substantial doubt about our ability to continue as a going concern. This ...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  To date, we have not generated any revenue, and we do not expect to                                                                          

  We have not generated revenue, have a history of losses, and expect to continue incurring losses. We will need substantial additional capital to advance our pipeline, including Quilience, Nolaz...  
  As a public company, we must comply with extensive U. S., Swiss, and Nasdaq regulations, which are costly and require significant management attention. We may be delisted from Nasdaq due to non...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We require regulatory approvals, including from the FDA and EMA, to commercialize our products;  

  Clinical data may not satisfy regulatory authorities or may require additional studies, delaying or preventing approval;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  As a foreign private issuer and an emerging growth company, we follow reduced U. S. reporting standards, which could impact investor confidence;    
  We have identified material weaknesses in our internal controls; failure to remediate them may impair financial reporting and harm investor trust;  

  If the Merger with Kadimastem is not consummated, NLS’s